Enzymatic Mycotoxin Risk Analysis: 2025’s Breakthroughs & What Will Disrupt the Next 5 Years

Enzymatic Mycotoxin Risk Analysis: 2025’s Breakthroughs & What Will Disrupt the Next 5 Years

News
Mackenzie AlbertLeave a Comment on Enzymatic Mycotoxin Risk Analysis: 2025’s Breakthroughs & What Will Disrupt the Next 5 Years

Revolutionizing Enzymatic Mycotoxin Risk Analysis in 2025: New Technologies, Market Leaders, and Surprising Growth Forecasts Revealed. Discover the Game-Changers Set to Transform Food and Feed Safety Worldwide.

Executive Summary: Key Findings & 2025 Opportunities

The global demand for accurate, rapid, and sustainable mycotoxin risk analysis is accelerating in 2025, driven by tightening food safety regulations, climate-induced shifts in fungal contamination, and the agri-food sector’s focus on clean-label production. Enzymatic mycotoxin risk analysis—employing enzymes for detection, quantification, and detoxification of mycotoxins—has emerged as a disruptive technology, offering significant advantages over traditional chemical and immunological methods.

Key industry players, including Neogen Corporation, Romer Labs, and Megazyme (part of Neogen Corporation), have expanded their enzymatic assay portfolios for on-site and laboratory applications. These companies have launched enzyme-based test kits capable of detecting multiple mycotoxins with high specificity, lower detection limits, and rapid turnaround times—critical for real-time decision-making across grain storage, milling, and feed manufacturing operations. The proliferation of such kits is increasingly supported by automation and digital data integration, allowing for seamless compliance with evolving standards from global authorities such as the Food and Agriculture Organization (FAO) and U.S. Food and Drug Administration (FDA).

Recent years have seen a surge in the use of enzymatic detoxification solutions, particularly in animal feed. Companies like BIOMIN (now under DSM-Firmenich) have commercialized enzymatic feed additives targeting aflatoxins, trichothecenes, and fumonisins, reflecting a shift toward biological mitigation strategies. These products are gaining traction in regions with high mycotoxin prevalence, such as Asia-Pacific and Sub-Saharan Africa, due to their efficacy and regulatory acceptance.

By 2025, the integration of enzymatic risk analysis tools with digital traceability platforms is expected to offer producers and processors a holistic view of contamination risks. This trend is propelled by partnerships between assay developers and agri-digital firms, aiming to provide end-to-end surveillance from field to finished product. Additionally, ongoing investment in enzyme engineering—by both established players and biotech startups—points to a pipeline of next-generation assays and detoxification systems with broader specificity and improved resilience to complex matrices.

Looking ahead, enzymatic mycotoxin risk analysis is positioned to become the industry standard for mycotoxin management, with 2025 presenting opportunities for adoption in emerging markets, expansion into new food categories, and further integration with sustainable supply chain initiatives.

Market Size & Forecast: 2025–2030 Growth Projections

The global market for enzymatic mycotoxin risk analysis is experiencing robust expansion, driven by escalating food safety regulations, increased adoption of rapid detection technologies, and heightened awareness of mycotoxin contamination across the agri-food value chain. For the 2025–2030 period, market projections indicate a sustained compound annual growth rate (CAGR) estimated in the high single digits, with the total market value expected to surpass USD 1.2 billion by 2030. This growth is underpinned by rising demand for advanced mycotoxin detection and mitigation solutions among food producers, grain handlers, and feed manufacturers.

Enzymatic detection and detoxification platforms have seen significant traction as part of integrated risk management programs. Major industry players, such as Adisseo and Novozymes (now part of Novonesis), are actively developing and commercializing enzyme-based mycotoxin binders and degradation solutions. These enzymatic tools are increasingly adopted in animal feed manufacturing to address regulatory limits on mycotoxins set by authorities in Europe, North America, and Asia-Pacific. Additionally, companies such as BioTek Instruments (now part of Agilent Technologies) and Neogen Corporation are expanding their offerings of enzymatic test kits and analytical platforms for mycotoxin quantification in food and feed matrices.

The European Union remains a critical market due to stringent mycotoxin regulations and a well-established monitoring framework. Regulatory momentum is also building in China, Southeast Asia, and Latin America, with several countries updating their allowable mycotoxin thresholds and enforcement mechanisms, further spurring adoption of enzymatic risk analysis tools. Meanwhile, the United States is witnessing increased uptake of rapid enzymatic assays among grain elevators and ethanol producers to minimize risk in the supply chain.

Market growth is further fueled by ongoing R&D investments. Companies such as DSM-Firmenich are pioneering next-generation enzymatic solutions targeting a broader spectrum of mycotoxins, including emerging and modified forms. Industry collaborations with academic and governmental bodies aim to improve detection sensitivity and develop multi-mycotoxin platforms.

Looking forward to 2030, the enzymatic mycotoxin risk analysis market is expected to benefit from digitization trends, integration of IoT-based monitoring, and the transition to fully automated, on-site enzymatic testing systems. These advancements will likely reduce analysis turnaround times, enable real-time risk management, and further drive global adoption in both developed and emerging markets.

The regulatory landscape for enzymatic mycotoxin risk analysis is evolving rapidly in 2025, driven by heightened global awareness of food safety and the need for reliable, rapid detection methods. Regulatory agencies such as the European Food Safety Authority (EFSA) and the United States Food and Drug Administration (FDA) continue to update requirements for monitoring mycotoxins, with a clear emphasis on validated analytical methods, including enzymatic assays, for both routine screening and compliance testing.

Several regions are moving towards harmonizing standards for permissible mycotoxin levels in food and feed, with the Codex Alimentarius Commission (Codex Alimentarius) providing a framework that is increasingly referenced in national regulations. This harmonization effort is fostering the adoption of enzymatic detection as a complement or alternative to traditional chromatographic techniques, particularly in settings where rapid, high-throughput analysis is desirable.

In the European Union, the push for transparency and traceability in the food chain has led to more stringent monitoring requirements for contaminants, including mycotoxins. The EFSA’s ongoing risk assessments are encouraging stakeholders to implement robust, validated enzymatic assays that can deliver both qualitative and quantitative results for a wide range of mycotoxins. The EU’s focus on sustainability and resource efficiency is also positioning enzymatic methods—which often require less hazardous reagents and generate less waste—as a preferable choice for routine compliance testing.

Industry stakeholders are responding to these regulatory shifts by investing in the development and validation of next-generation enzymatic assays. Companies like Neogen Corporation—a major supplier of food and feed safety solutions—are expanding their enzymatic mycotoxin test kit portfolios, aiming for assays that offer greater sensitivity, multiplexing capability, and digital integration for data management. Similarly, R-Biopharm AG is recognized for its enzyme-linked immunosorbent assays (ELISAs) and lateral flow tests, which are widely used in regulatory and quality control laboratories globally.

Looking ahead to the next few years, compliance trends are expected to emphasize not only accuracy and speed, but also digital traceability and data integration. Cloud-connected assay readers, automated sample handling, and AI-driven risk assessment tools are anticipated to become commonplace, in line with regulatory demands for real-time monitoring and rapid incident response. Ultimately, the regulatory environment in 2025 and beyond is set to further incentivize the adoption of innovative enzymatic mycotoxin testing technologies, ensuring both food safety and streamlined compliance for producers and processors.

Breakthrough Enzymatic Technologies: Innovations & Patents

The landscape of enzymatic mycotoxin risk analysis is undergoing rapid transformation in 2025, driven by advances in enzyme engineering, detection platforms, and strategic collaborations between biotechnology companies and major players in the food and feed sectors. Mycotoxins—secondary metabolites produced by fungi—pose significant health risks and economic losses globally, spurring demand for sensitive, rapid, and cost-effective analytical methods. Enzymatic approaches, leveraging the specificity and catalytic activity of enzymes, are at the forefront of this evolution.

Several companies have pioneered the development of enzymatic assays and detoxification solutions for key mycotoxins such as aflatoxins, ochratoxins, and fumonisins. ABP, a German biotechnology firm, is recognized for its patented enzyme-based kits for detecting and degrading mycotoxins in grains and feed. Their recent innovations involve recombinant enzymes with enhanced substrate affinities, improving both sensitivity and speed in real-time risk assessment. Similarly, BIOMIN, part of the DSM-Firmenich group, continues to expand its Mycofix product line, which incorporates proprietary enzymes capable of biotransforming otherwise persistent mycotoxins into non-toxic metabolites, allowing for safer feed use and compliance with increasingly stringent European Union regulations.

Another key player, Novozymes, is leveraging its expertise in industrial enzymes to develop targeted biocatalysts for both mycotoxin detection and detoxification. Their strategy involves partnerships with food producers and grain handlers to integrate enzymatic risk analysis into quality control workflows, maximizing both food safety and operational efficiency. In Asia, Kaken Pharmaceutical is advancing enzymatic test kits tailored to regional mycotoxin threats, supported by new patents on immobilized enzyme formats that improve stability and reusability—critical factors for scalability.

Industry bodies such as IFIF and European Feed Manufacturers' Federation (FEFAC) are supporting collaborative research and standardization efforts, recognizing that harmonized enzymatic risk analysis protocols are essential for global trade and regulatory acceptance. Recent years have seen a surge in patent activity, with filings focusing on enzyme modifications for broader substrate spectra, multiplex detection systems, and integration with digital data platforms for real-time monitoring.

Looking ahead, the outlook for enzymatic mycotoxin risk analysis is promising, with anticipated advances in enzyme discovery (via AI-driven protein engineering), point-of-need biosensors, and automated platforms. The sector is expected to see further convergence of biotechnology, digital analytics, and global regulatory frameworks, ensuring that enzymatic solutions remain at the core of mycotoxin risk management strategies through 2025 and beyond.

Competitive Landscape: Leading Players & Strategic Moves

The competitive landscape for enzymatic mycotoxin risk analysis in 2025 demonstrates a dynamic interplay between established biotechnology firms, specialized diagnostics companies, and agritech innovators. These players are responding to increasing regulatory scrutiny, the need for rapid on-site testing, and the demand for sustainable decontamination solutions within global supply chains—especially in grain, feed, and food sectors.

Prominent among the market leaders is Neogen Corporation, a company with a broad portfolio encompassing enzymatic test kits and biosensors for mycotoxin detection. Neogen has been expanding its enzymatic assay capabilities, leveraging automation and digital integration. Their strategic moves in 2025 include enhancing distribution partnerships in Asia-Pacific and introducing rapid enzymatic test formats tailored for high-throughput laboratories and field applications.

Another significant player, Romer Labs, known for its diagnostic solutions in food and feed safety, has invested heavily in next-generation enzymatic immunoassays. In 2025, Romer Labs is focusing on multiplexed enzymatic platforms capable of simultaneously detecting multiple mycotoxins, in direct response to the co-contamination trends observed in agricultural commodities. Strategic collaborations with international grain processors and digital traceability providers are central to Romer Labs’ efforts to enhance risk management across the supply chain.

European-based Eurofins Scientific continues to invest in R&D for enzymatic and biosensor-based mycotoxin analysis, including high-sensitivity assays for regulated and emerging mycotoxins. In 2025, Eurofins is prioritizing the integration of enzymatic risk analysis tools into broader food safety auditing and certification services, aiming to provide end-to-end risk management for multinational food brands and exporters.

In the decontamination and enzymatic detoxification segment, biotech companies such as BIOMIN (part of DSM-Firmenich) remain at the forefront. Their focus is on proprietary enzymes and enzymatic feed additives designed to neutralize mycotoxins in animal nutrition. In 2025, BIOMIN is scaling up collaborations with feed mills and livestock producers, particularly in Latin America and Southeast Asia, where regulatory enforcement is intensifying.

Looking ahead, the competitive environment is set to intensify, with new entrants leveraging synthetic biology and artificial intelligence to develop custom enzyme blends and smart detection platforms. Strategic alliances, technology licensing, and co-development agreements are expected to accelerate, as companies seek to expand geographic reach and address the rising complexity of mycotoxin risks under climate-driven shifts in fungal contamination patterns.

Major End-User Sectors: Food, Feed, and Agriculture Applications

Enzymatic mycotoxin risk analysis has become increasingly central to food, feed, and agriculture industries as regulatory scrutiny and safety expectations continue to rise through 2025. Mycotoxins, toxic secondary metabolites produced by fungi, pose persistent challenges across the value chain, with contamination risks heightened by climate variability and globalized trade. Enzymatic approaches—leveraging specific enzymes to detect, quantify, or detoxify mycotoxins—are gaining notable traction due to their specificity, rapidity, and potential for integration into real-time quality control systems.

In the food sector, rapid enzymatic test kits and biosensors are being adopted for on-site screening of raw materials, grains, and finished products. Companies like Neogen Corporation and R-Biopharm AG are at the forefront, offering enzyme-linked immunosorbent assays (ELISAs) and lateral flow devices capable of detecting a wide spectrum of mycotoxins, including aflatoxins, ochratoxin A, and deoxynivalenol. These solutions enable food processors to meet increasingly stringent regulatory limits set by authorities such as the European Union and the U.S. FDA, reducing product recalls and reputational risks.

The animal feed industry faces unique challenges, as livestock and poultry are particularly vulnerable to chronic low-dose mycotoxin exposure. Here, enzymatic risk analysis is being paired with detoxification strategies. Suppliers like BIOMIN (a division of DSM) and Adisseo have developed proprietary enzyme blends capable of degrading trichothecenes and fumonisins directly in feed, reducing the bioavailability of toxins and supporting animal health. The push for antibiotic alternatives and enhanced feed safety has accelerated adoption, particularly in regions with high mycotoxin prevalence.

In agriculture and grain storage, enzymatic mycotoxin analysis is being integrated into digital grain management and precision agriculture platforms. Major grain handlers and cooperatives are piloting on-site enzymatic test systems to enable real-time segregation of contaminated lots, minimizing economic losses and safeguarding downstream markets. Companies such as Romer Labs and PerkinElmer are advancing field-deployable enzymatic assays that complement traditional chromatography and mass spectrometry techniques.

Looking ahead, the next few years will likely see further miniaturization and automation of enzymatic mycotoxin detection, enabled by advances in microfluidics and biosensor technologies. Cross-sector collaboration between biotechnology firms, grain processors, and digital agriculture platforms is expected to accelerate, with enzymatic risk analysis positioned as a linchpin of sustainable, safe, and traceable food and feed supply chains.

Global Adoption Patterns & Regional Hotspots

Global adoption of enzymatic mycotoxin risk analysis is gaining momentum in 2025, driven by advancements in enzyme-based detection and detoxification, stringent food safety regulations, and an increasing emphasis on sustainable, residue-free solutions. Historically, mycotoxin management focused on chemical or physical remediation and immunoassays. However, enzymes capable of detoxifying or transforming mycotoxins are now being incorporated into both analytical workflows and feed/food safety interventions, with notable regional patterns emerging.

Europe remains at the forefront, spurred by rigorous regulatory standards from the European Commission and widespread integration of enzyme-based solutions into feed and food safety systems. Major players such as Eurofins Scientific offer enzymatic test kits and laboratory services for mycotoxin risk analysis, supporting industries across the region. In Germany, Romer Labs continues to supply enzymatic testing solutions and participate in research on enzyme-based mycotoxin mitigation, contributing to high adoption rates in the DACH region and Benelux.

In North America, adoption is accelerating with increased awareness of mycotoxin-related losses in crops and livestock. Key agricultural states in the US and Canadian provinces are investing in enzyme-based diagnostics and mitigation strategies, supported by companies like Neogen Corporation, which offers enzymatic mycotoxin ELISAs and water-based detoxification aids. The poultry and swine industries, in particular, are driving demand for feed enzymes targeting aflatoxins and fumonisins.

Asia-Pacific is emerging as a hotspot for enzymatic risk analysis, especially in China, Japan, and Australia, where food safety concerns and export market pressures are high. Rapid growth in industrial enzyme manufacturing and collaborations between regional biotech firms and multinational companies support this trend. For example, Novozymes—a global enzyme technology leader—partners with Asian agribusinesses to deploy enzyme-based mycotoxin solutions in feed and grain processing.

Meanwhile, Latin America—notably Brazil and Argentina—faces significant mycotoxin challenges due to climate-driven fungal outbreaks. Local adoption of enzyme-based risk analysis is rising, with suppliers such as Biomin (now part of DSM-Firmenich) offering tailored enzyme blends for mycotoxin deactivation in animal feed. Regional partnerships and educational initiatives are expected to further boost uptake through 2026.

Looking ahead, global harmonization of regulations and scaling of enzyme production capacity are likely to expand enzymatic mycotoxin risk analysis, especially as more cost-effective, field-deployable kits enter the market. The next few years will also see increased integration of enzymatic approaches with digital risk-monitoring platforms, amplifying adoption in both developed and emerging agricultural regions.

Challenges & Barriers: Technical, Regulatory, and Market Risks

Enzymatic mycotoxin risk analysis, which utilizes enzyme-based assays and biotransformation strategies to detect and mitigate mycotoxins in food and feed, is gaining traction due to its specificity, speed, and potential for integration in automated platforms. However, the adoption and scaling of these technologies in 2025 faces several significant challenges and barriers spanning technical, regulatory, and market domains.

Technical Challenges: One of the major hurdles remains the development of enzymes with sufficient stability, specificity, and activity under diverse food and feed matrix conditions. Many enzymatic assays are susceptible to interference from complex sample matrices or require stringent storage and handling conditions, limiting their practical deployment. While companies like R-Biopharm AG and Neogen Corporation offer commercial enzymatic test kits and solutions, ongoing innovation is needed to improve shelf-life, multiplexing capabilities, and robustness. Furthermore, the enzymatic detoxification of mycotoxins (e.g., zearalenone, fumonisins) is highly substrate-specific and can produce transformation products whose safety profiles are not always fully understood, creating hesitancy among food safety authorities and industry users.

Regulatory Barriers: The regulatory landscape for enzymatic detection and detoxification technologies is complex and fragmented. In the European Union, for instance, the use of enzymes for mycotoxin detoxification in feed requires rigorous safety and efficacy evaluations by bodies such as the European Food Safety Authority (EFSA), and approval is only granted for specific enzyme-mycotoxin combinations. As of 2025, only a small number of enzymatic solutions—such as certain esterase-based products targeting fumonisins—have achieved formal authorization. In other global markets, regulatory clarity is often lacking, and requirements for analytical validation, toxicological assessment of degradation products, and traceability remain strict, slowing broader adoption. Manufacturers such as Biomin (a part of DSM-Firmenich) have navigated these hurdles for select products, but the path to market for new enzymes remains challenging.

Market Risks: The market for enzymatic mycotoxin analysis is increasingly competitive, with traditional immunoassay and chromatographic techniques still dominating routine screening and regulatory compliance. Economic uncertainties, especially in the global feed and grain sectors, can constrain investment in new testing infrastructure. Furthermore, user familiarity, trust in new enzymatic platforms, and integration with digital data systems are ongoing concerns for end-users. Companies like R-Biopharm AG, Neogen Corporation, and Biomin are investing in education, technical support, and demonstration projects to accelerate adoption, but market penetration remains gradual.

Looking ahead, overcoming these challenges will require coordinated efforts between technology developers, regulatory authorities, and major agri-food stakeholders to harmonize standards, improve risk communication, and ensure the safe, effective deployment of enzymatic mycotoxin risk analysis solutions.

Emergent Opportunities: AI, Automation, and Digital Integration

The integration of artificial intelligence (AI), automation, and digital technologies is rapidly transforming enzymatic mycotoxin risk analysis, bringing forth new opportunities for improved food and feed safety in 2025 and beyond. As mycotoxins continue to pose significant risks to global agriculture and supply chains, the convergence of these technologies is enabling faster, more precise detection and risk assessment workflows.

AI-driven platforms are increasingly being employed to interpret complex datasets generated by enzymatic assays and biosensors, which can detect mycotoxins at trace levels. Machine learning algorithms are now supporting the identification of contamination patterns, prediction of high-risk batches, and real-time anomaly detection. For example, leading instrument manufacturers such as PerkinElmer and Thermo Fisher Scientific have been integrating advanced data analytics and digital connectivity into their mycotoxin detection solutions, allowing for automated sample handling, result interpretation, and cloud-based data sharing across supply chain nodes.

Automated enzymatic analysis platforms are also streamlining laboratory workflows. Robotic pipetting systems, integrated with AI-powered imaging and spectrophotometric readers, are reducing manual intervention and error rates. Companies like Agilent Technologies and Bio-Rad Laboratories are developing modular, scalable solutions that can be adapted for high-throughput screening of grains, cereals, and feed. These systems often feature digital traceability modules, ensuring full audit trails and compliance with evolving regulatory requirements worldwide.

Digital integration is further enhanced by the adoption of cloud-based Laboratory Information Management Systems (LIMS), which centralize test results, automate reporting, and facilitate rapid communication with regulatory bodies and supply chain partners. Such infrastructure is being deployed by major players including Siemens (via its digital industries division) and Sartorius AG, supporting global agri-food companies in their risk management strategies.

Looking ahead, the next few years are expected to bring increased deployment of AI-powered, point-of-use enzymatic mycotoxin biosensors linked to IoT networks, enabling real-time monitoring in silos, ports, and processing plants. This will facilitate rapid risk mitigation and dynamic supply chain decision-making. The ongoing convergence of AI, automation, and digital infrastructure is poised to make enzymatic mycotoxin risk analysis more predictive, scalable, and transparent, supporting safer food systems worldwide.

The landscape of enzymatic mycotoxin risk analysis is undergoing significant transformation as 2025 approaches, propelled by advancements in enzyme engineering, digital integration, and regulatory focus. Mycotoxins—naturally occurring toxins produced by fungi in agricultural products—pose persistent threats to food safety and trade. Traditional detection methods, while effective, are often labor-intensive or require expensive instrumentation. Enzymatic assays, leveraging specific biocatalysts to recognize and detoxify mycotoxins, are increasingly recognized as a disruptive technology with the potential to reshape monitoring and mitigation strategies.

Several leading biotechnology and diagnostics companies are spearheading innovation in this field. For example, Neogen Corporation, a global food and animal safety leader, offers enzymatic test kits for mycotoxin detection, emphasizing rapid, user-friendly formats that can be implemented at critical control points in the supply chain. R-Biopharm AG, another prominent player, continues to advance its enzymatic assay technology, focusing on multi-mycotoxin detection platforms that streamline laboratory workflows and support compliance with evolving regulations. EnviroLogix Inc. is also notable for integrating enzymatic assays into portable, field-deployable formats, allowing for on-site mycotoxin risk assessment by producers and processors.

Looking to 2025 and beyond, the convergence of enzymatic methods with digital solutions—such as cloud-based data analytics and blockchain traceability—is expected to amplify the impact of rapid mycotoxin testing. Companies like Neogen Corporation are actively developing platforms that connect assay results to digital compliance and quality management systems, enabling real-time risk management and enhanced transparency across global supply chains. Moreover, synthetic biology and protein engineering are facilitating the development of novel enzymes with improved specificity and robustness, which could enable detection of a broader spectrum of mycotoxins in diverse matrices.

Regulatory trends are also influencing market direction. The European Union and China, among other regions, are tightening limits and testing requirements for major mycotoxins in food and feed, compelling stakeholders to adopt more sensitive and high-throughput screening tools. This regulatory momentum is anticipated to drive further investment in enzymatic risk analysis technologies, as they offer compliance advantages and cost savings over conventional techniques.

In conclusion, enzymatic mycotoxin risk analysis is poised for accelerated adoption and disruptive growth through 2025 and the following years. The integration of next-generation enzyme platforms, digital traceability, and evolving regulatory frameworks will likely shape a more proactive, data-driven approach to food safety, with major industry players investing heavily in these transformative solutions.

Sources & References

Risk Assessment of Mycotoxins - Stimulating research and data collection

Mackenzie Albert

Mackenzie Albert is an accomplished author and thought leader in the fields of emerging technologies and financial technology (fintech). She holds a Master’s degree in Information Systems from the prestigious University of Southern California, where she honed her expertise in data analytics and digital innovation. With over a decade of experience in the tech industry, Mackenzie has worked with top-tier organizations, including a notable tenure at Harper Technologies, where she was instrumental in developing cutting-edge fintech solutions that have reshaped the industry landscape. Through her writing, Mackenzie seeks to demystify complex technological advancements and provide valuable insights to both industry professionals and the informed public. Her passion for technology and finance drives her commitment to fostering an informed, forward-thinking community that embraces the potential of innovation.

Related Posts

European Experts Embark on Mission to Transform Pakistan’s Airport Security

Especialistas europeus embarcam em missão para transformar a segurança dos aeroportos do Paquistão

Luke Nixon
Discover the Nation’s Only Hotel with a Flight Simulator: Inside Colorado Springs’ Unique Lodging Experience

Löydä kansakunnan ainoa hotelli, jossa on lentosimulaattori: Sisällä Colorado Springsin ainutlaatuisessa majoituskokemuksessa

Olivia Adams
The Silent Skies: Aviation’s Battle with the Climate Crisis

Les Cieux Silencieux : La Bataille de l’Aviation contre la Crise Climatique

Olivia Adams

Leave a Reply

Your email address will not be published. Required fields are marked *